Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

2.555 -0.205 (-7.43%)
Streaming Delayed Price Updated: 12:22 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
Via Benzinga
Why Shares of MaxCyte Are Plummeting on Thursday
The biotech company reduced full-year guidance and expects so-so third-quarter revenue. 
Via The Motley Fool
Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.45% to 32,980.31 while the NASDAQ fell 0.62% to 13,154.24. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: MaxCyte Q1 Earnings
Via Benzinga
Looking Into MaxCyte's Return On Capital Employed
Via Benzinga
BB Stock Alert: What to Know as BlackBerry Plans IPO for IoT Division
BlackBerry stock is a hot topic among BB shareholders today alongside news the company is considering an IPO for its IoT business. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is MaxCyte (MXCT) Stock Down 21% Today?
MaxCyte stock is taking a beating on Thursday as investors in MXCT shares react to preliminary results for its third quarter of 2023. 
Via InvestorPlace
Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
Via InvestorPlace
MaxCyte, Rivian Automotive And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Conagra Brands, Constellation Brands And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Baird Global Healthcare Conference
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative... 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales. 
Via Benzinga
Disney, Sonos, Desktop Metal And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. Sonos, Inc. (NASDAQ: SONO) shares dipped 25.2% to $15.82 in pre-market... 
Via Benzinga
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases 
From MaxCyte, Inc
Via GlobeNewswire
7 Small-Cap Biotech Stocks with Massive Potential
Although small-cap biotech stocks present high risks, if they hit one out of the park, the rewards can be astronomical. 
Via InvestorPlace
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
From MaxCyte, Inc
Via GlobeNewswire
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ... 
Via Benzinga
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
From MaxCyte, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.